259 related articles for article (PubMed ID: 23002953)
41. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
42. Fully Automated Convolutional Neural Network Method for Quantification of Breast MRI Fibroglandular Tissue and Background Parenchymal Enhancement.
Ha R; Chang P; Mema E; Mutasa S; Karcich J; Wynn RT; Liu MZ; Jambawalikar S
J Digit Imaging; 2019 Feb; 32(1):141-147. PubMed ID: 30076489
[TBL] [Abstract][Full Text] [Related]
43. Randomized trial of 2 versus 5 years of adjuvant tamoxifen for women aged 50 years or older with early breast cancer: Italian Interdisciplinary Group Cancer Evaluation Study of Adjuvant Treatment in Breast Cancer 01.
Sacco M; Valentini M; Belfiglio M; Pellegrini F; De Berardis G; Franciosi M; Nicolucci A;
J Clin Oncol; 2003 Jun; 21(12):2276-81. PubMed ID: 12805326
[TBL] [Abstract][Full Text] [Related]
44. Diffusion tensor imaging in the normal breast: influences of fibroglandular tissue composition and background parenchymal enhancement.
Plaza MJ; Morris EA; Thakur SB
Clin Imaging; 2016; 40(3):506-11. PubMed ID: 27133695
[TBL] [Abstract][Full Text] [Related]
45. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Background Parenchymal Enhancement at Contrast-enhanced Spectral Mammography and Breast MR Imaging.
Sogani J; Morris EA; Kaplan JB; D'Alessio D; Goldman D; Moskowitz CS; Jochelson MS
Radiology; 2017 Jan; 282(1):63-73. PubMed ID: 27379544
[TBL] [Abstract][Full Text] [Related]
47. Decreased background parenchymal enhancement of the contralateral breast after two cycles of neoadjuvant chemotherapy is associated with tumor response in HER2-positive breast cancer.
You C; Gu Y; Peng W; Li J; Shen X; Liu G; Peng W
Acta Radiol; 2018 Jul; 59(7):806-812. PubMed ID: 29065702
[TBL] [Abstract][Full Text] [Related]
48. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
Chen JH; Yu H; Lin M; Mehta RS; Su MY
Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
[TBL] [Abstract][Full Text] [Related]
49. Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.
Arasu VA; Miglioretti DL; Sprague BL; Alsheik NH; Buist DSM; Henderson LM; Herschorn SD; Lee JM; Onega T; Rauscher GH; Wernli KJ; Lehman CD; Kerlikowske K
J Clin Oncol; 2019 Apr; 37(12):954-963. PubMed ID: 30625040
[TBL] [Abstract][Full Text] [Related]
50. The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer.
Mema E; Schnabel F; Chun J; Kaplowitz E; Price A; Goodgal J; Moy L
Eur J Radiol; 2020 Mar; 124():108813. PubMed ID: 31927471
[TBL] [Abstract][Full Text] [Related]
51. Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response.
Onishi N; Li W; Newitt DC; Harnish RJ; Strand F; Nguyen AA; Arasu VA; Gibbs J; Jones EF; Wilmes LJ; Kornak J; Joe BN; Price ER; Ojeda-Fournier H; Eghtedari M; Zamora KW; Woodard S; Umphrey HR; Nelson MT; Church AL; Bolan PJ; Kuritza T; Ward K; Morley K; Wolverton D; Fountain K; Lopez Paniagua D; Hardesty L; Brandt KR; McDonald ES; Rosen M; Kontos D; Abe H; Sheth D; Crane E; Dillis C; Sheth P; Hovanessian-Larsen L; Bang DH; Porter B; Oh KY; Jafarian N; Tudorica LA; Niell B; Drukteinis J; Newell MS; Giurescu ME; Berman E; Lehman CD; Partridge SC; Fitzpatrick KA; Borders MH; Yang WT; Dogan B; Goudreau SH; Chenevert T; Yau C; DeMichele A; Berry DA; Esserman LJ; Hylton NM
Radiology; 2021 Nov; 301(2):295-308. PubMed ID: 34427465
[TBL] [Abstract][Full Text] [Related]
52. Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study.
Watt GP; Thakran S; Sung JS; Jochelson MS; Lobbes MBI; Weinstein SP; Bradbury AR; Buys SS; Morris EA; Apte A; Patel P; Woods M; Liang X; Pike MC; Kontos D; Bernstein JL
Radiology; 2023 Sep; 308(3):e230367. PubMed ID: 37750771
[TBL] [Abstract][Full Text] [Related]
53. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
54. Correlation of background parenchymal enhancement on breast MRI with breast cancer.
Sallam H; Lenga L; Solbach C; Becker S; Vogl TJ
Clin Radiol; 2023 Sep; 78(9):e654-e659. PubMed ID: 37330320
[TBL] [Abstract][Full Text] [Related]
55. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
[TBL] [Abstract][Full Text] [Related]
56. Automated rating of background parenchymal enhancement in MRI of extremely dense breasts without compromising the association with breast cancer in the DENSE trial.
Wang H; H M van der Velden B; Verburg E; Bakker MF; Pijnappel RM; Veldhuis WB; van Gils CH; Gilhuijs KGA
Eur J Radiol; 2024 Jun; 175():111442. PubMed ID: 38583349
[TBL] [Abstract][Full Text] [Related]
57. Generalizable attention U-Net for segmentation of fibroglandular tissue and background parenchymal enhancement in breast DCE-MRI.
Nowakowska S; Borkowski K; Ruppert CM; Landsmann A; Marcon M; Berger N; Boss A; Ciritsis A; Rossi C
Insights Imaging; 2023 Nov; 14(1):185. PubMed ID: 37932462
[TBL] [Abstract][Full Text] [Related]
58. MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women.
Brooks JD; Christensen RAG; Sung JS; Pike MC; Orlow I; Bernstein JL; Morris EA
NPJ Breast Cancer; 2022 Aug; 8(1):97. PubMed ID: 36008488
[TBL] [Abstract][Full Text] [Related]
59. Background parenchymal enhancement in breast MRI before and after neoadjuvant chemotherapy: correlation with tumour response.
Preibsch H; Wanner L; Bahrs SD; Wietek BM; Siegmann-Luz KC; Oberlecher E; Hahn M; Staebler A; Nikolaou K; Wiesinger B
Eur Radiol; 2016 Jun; 26(6):1590-6. PubMed ID: 26382845
[TBL] [Abstract][Full Text] [Related]
60. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI; Shepherd LE; Chapman JA; Norris BD; Cantin J; Goss PE; Dent SF; Walde D; Vandenberg TA; Findlay B; O'Reilly SE; Wilson CF; Han L; Piura E; Whelan TJ; Pollak MN
J Clin Oncol; 2011 Oct; 29(29):3869-76. PubMed ID: 21911723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
